A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; none of the 16 sources its claims cite is checked for support yet.
Abstract
BACKGROUND: Some probiotics have shown efficacy for patients with irritable bowel syndrome (IBS). Lactobacillus (L.) plantarum MF1298 was found to have the best in vitro probiotic properties of 22 strains of lactobacilli. The aim of this study was to investigate the symptomatic effect of L. plantarum MF1298 in subjects with IBS. Primary outcome was treatment preference and secondary outcomes were number of weeks with satisfactory relief of symptoms and IBS sum score. METHODS: The design was a randomised double blind placebo-controlled crossover trial. 16 subjects with IBS underwent two three-week periods of daily intake of one capsule of 10(10) CFU L. plantarum MF 1298 or placebo separated by a four-week washout period. RESULTS: Thirteen participants (81%; 95% CI 57% to 93%; P = 0.012) preferred placebo to L. plantarum MF1298 treatment. The mean (SD) number of weeks with satisfactory relief of symptoms in the periods with L. plantarum MF1298 and placebo were 0.50 (0.89) and 1.44 (1.26), respectively (P = 0.006). IBS sum score was 6.44 (1.81) in the period with L. plantarum MF1298 treatment compared with 5.35 (1.77) in the period with placebo (P = 0.010). With a clinically significant difference in the IBS sum score of 2 in disfavour of active treatment, the number needed to harm was 3.7, 95% CI 2.3 to 10.9. CONCLUSIONS: This trial shows for the first time an unfavourable effect on symptoms in subjects with IBS after intake of a potential probiotic.
Overview
CoChat Summary
TL;DR
In a randomised double-blind placebo-controlled crossover trial, subjects with IBS reported worse symptoms during intake of the candidate probiotic *Lactobacillus plantarum* MF1298 than during placebo. The authors conclude this is the first trial showing an unfavourable symptomatic effect of a potential probiotic in IBS.
Key findings
- Thirteen of 16 participants (81%; 95% CI 57% to 93%; P = 0.012) preferred placebo to *L. plantarum* MF1298.
- Mean (SD) weeks with satisfactory relief of symptoms were 0.50 (0.89) with *L. plantarum* MF1298 versus 1.44 (1.26) with placebo (P = 0.006).
- IBS sum score was 6.44 (1.81) with *L. plantarum* MF1298 versus 5.35 (1.77) with placebo (P = 0.010); the difference was 1.09 (1.47), and the number needed to harm was 3.7 (95% CI 2.3 to 10.9) for a clinically significant ≥2-point difference in disfavour of active treatment.
- Diarrhoea score was also higher with active treatment: 6.36 (1.99) versus 5.50 (1.71) with placebo (P = 0.004).
Methods
- Randomised, double-blind, placebo-controlled crossover trial with a one-week run-in, two three-week treatment periods, and a four-week washout; 16 subjects with IBS according to Rome II criteria were analysed after daily intake of one capsule of 10^10 CFU *L. plantarum* MF1298 or placebo.
- Primary outcome was treatment preference; secondary outcomes were number of weeks with satisfactory relief of symptoms and IBS sum score; faecal *L. plantarum* was assessed by real-time PCR, and adverse events were noted.
- Analysis used modified intention-to-treat; paired and independent t tests, Wilson method for preference CI/P value, marginal homogeneity test for satisfactory relief, and Walter’s method for number needed to harm.
Limitations
- The paper states that heterogeneity in bowel-habit predominance meant it could not identify aggravation of a specific symptom, that a type I error cannot be excluded, and that the IBS sum score was not validated for responsiveness or clinically significant differences; the chosen 2-point difference may be high given the run-in mean of 5.97.
- The authors also note older age and a somewhat different IBS subgroup distribution than in corresponding studies, raising questions about external validity, and state that a longer intervention would have strengthened internal validity but increased drop-out.
- Evident from the text: the analysed sample was small (16 participants), treatment periods were short (three weeks each), and endotoxins in the preparations were not checked.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
0 Valid · 0 Not valid · 12 Not checked · 34 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean (SD) number of weeks with satisfactory relief of symptoms in the periods with L. plantarum MF1298 and placebo were 0.50 (0.89) and 1.44 (1.26), respectively (P = 0.006).”
§ A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subclasses of IBS (diarrhoea predominant, constipation predominant, and alternating) showed the same tendency for higher IBS sum scores in the period with L. plantarum MF1298 compared with placebo (data not shown).”
§ A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial > Results
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IBS sum score was 6.44 (1.81) in the period with L. plantarum MF1298 treatment compared with 5.35 (1.77) in the period with placebo (P = 0.010).”
- Also stated in: § Results · plain
“The IBS sum score in the active period was 6.44 (1.81), in the placebo period 5.35 (1.77), and the correlation between these was 0.66.”
§ A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial > Abstract > Results
plainn = 13 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thirteen participants (81%; 95% CI 57% to 93%; P = 0.012) preferred placebo to L. plantarum MF1298 treatment.”
- Also stated in: § Results · plain
“Thirteen participants (81%; CI 57% to 93%; P = 0.012) preferred placebo to L. plantarum MF1298 treatment.”
§ A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial > Abstract > Results
plainn = 13 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“L. plantarum MF1298 was therefore proposed as a potential candidate probiotic strain.”
§ A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial > Background
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 46 claims and to verify the 16 references still open.
- It may state two separate claims as one. 18
- The quote only partly states this claim. 1
- Probably not a substantial claim. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Probiotics tested to date do not reduce diarrhea in patients with IBS Very low [174,179,181-183,185,187]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [182]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Twelve studies evaluated abdominal pain as a secondary end point only. Results from these studies were mixed: one reported a negative effect of the specific probiotic treatment,59 eight (examining six different probiotics) reported no significant effect28–38 and three reported a significant beneficial effect of three different probiotics35,39”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [59]
In the citing paper
“In only one study was there symptom deterioration221 although some large, high quality trials have been negative.221 231 234 235”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [221]
In the citing paper
“The safety of probiotics in IBS is acceptable but some aggravate symptoms221 and so patients should be warned of this possibility.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [221]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial > Results
“The IBS sum score at run-in was 6.21 (1.63)”
§ A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial > Discussion > Strengths and weaknesses
“the mean IBS sum score in the run-in period was 5.97”
Citations
Cites
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
Besselink, M. G., van Santvoort, H. C., Buskens, E., Boermeester, M. A., van Goor, H., Timmerman, H. M., Nieuwenhuijs, V. B., Bollen, T. L., van Ramshorst, B., Witteman, B. J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60207-x · Cited by 1,367
Guidelines on the irritable bowel syndrome: mechanisms and practical management
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., et al. (2007) · Gut · doi:10.1136/gut.2007.119446 · Cited by 818
Whorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'Mahony, L., Kiely, B., Shanahan, F., & Quigley, E. M. M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00734.x · Cited by 799
Probiotic use in clinical practice: what are the risks?
Boyle, R. J., Robins-Browne, R. M., & Tang, M. L. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1256 · Cited by 776 · cited 2×
“It has been proposed that the most potent probiotics may have increased pathogenicity [21].”
BackgroundNobaek, S., Johansson, M.-L., Molin, G., Ahrné, S., & Jeppsson, B. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02015.x · Cited by 653
Niedzielin, K., Kordecki, H., & Birkenfeld, B. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200110000-00004 · Cited by 506
Zoetendal, E. G., Vaughan, E. E., & De Vos, W. M. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05056.x · Cited by 389
KAJANDER, K., MYLLYLUOMA, E., RAJILIĆ‐STOJANOVIĆ, M., KYRÖNPALO, S., RASMUSSEN, M., JÄRVENPÄÄ, S., ZOETENDAL, E. G., DE VOS, W. M., VAPAATALO, H., & KORPELA, R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03542.x · Cited by 367
GUYONNET, D., CHASSANY, O., DUCROTTE, P., PICARD, C., MOURET, M., MERCIER, C. ‐., & MATUCHANSKY, C. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03362.x · Cited by 365
Research works printed but not linked: 1
- FAO/WHO Expert Consultation Group: Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001, Argentina: FAO/WHO
Cited by
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
“229 233 In only one study was there symptom deterioration(221) although some large, high quality trials have been negative.(221) 231 234 235”
BackgroundPetra, A. I., Panagiotidou, S., Hatziagelaki, E., Stewart, J. M., Conti, P., & Theoharides, T. C. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.04.002 · Cited by 592
Immunomodulatory mechanisms of lactobacilli
Wells, J. M. (2011) · Microbial Cell Factories · doi:10.1186/1475-2859-10-s1-s17 · Cited by 427
Tsilingiri, K., & Rescigno, M. (2013) · Beneficial Microbes · doi:10.3920/bm2012.0046 · Cited by 382
Didari, T. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i10.3072 · Cited by 356
Metadata
- Authors
- Ligaarden, S. C., Axelsson, L., Naterstad, K., Lydersen, S., & Farup, P. G.
- Affiliations
- Innlandet Hospital Trust (NO)
- Nofima (NO)
- Norwegian University of Science and Technology (NO)
- Corresponding author
- Ligaarden, Solveig C
- Venue
- BMC Gastroenterology
- Published
- 2010-02-10
- Volume
- 10
- Issue
- 1
- Pages
- 16-16
- ISSN
- 1471-230X (ISSN-L)
- PMC
- PMC2831047
- OpenAlex
- W2037366651
- Cited by
- 103
- References
- 26
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 13 · 2013: 6 · 2012: 14
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- BMC Gastroenterology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, probiotics, treatment preferences, symptom relief, number needed to harm, placebo comparison
- MeSH terms
- Adult, Aged, Constipation, Diarrhea, Feces, Female, Humans, Male, Middle Aged, Species Specificity, Abdominal Pain, Patient Satisfaction, Probiotics, Irritable Bowel Syndrome, Lactiplantibacillus plantarum
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. https://app.cochat.ai/papers/10.1186/1471-230x-10-16
- The paper
- Ligaarden, S. C., Axelsson, L., Naterstad, K., Lydersen, S., & Farup, P. G. (2010). A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterology. https://doi.org/10.1186/1471-230x-10-16
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

